Abstract: In a method for controlling sample introduction in microcolumn separation techniques, more particularly in capillary electrophoresis (CE), where a sample is injected as a sample plug into a sampling device which comprises at least a channel for the electrolyte buffer and a supply and drain channel for the sample. The supply and drain channels discharge into the electolyte channel at respective supply and drain ports. The distance between the supply port and the drain port geometrically defines a sample volume. The injection of the sample plug into the electrolyte channel is accomplished electrokinetically by applying an electric field across the supply and drain channels for a time at least long enough that the sample component having the lowest electrophoretic mobility is contained within the geometrically defined volume. The supply and drain channels each are inclined to the electrolyte channel. Means are provided for electrokinetically injecting the sample into the sample volume.

Abstract: The invention provides pharmaceutical formulations and methods for the treatment of individuals suffering from a condition, disease, or disorder that is treatable by the inhibition of angiogenesis. The compositions comprise a Golgi apparatus disturbing agent in a substantially nontoxic amount effective to inhibit angiogenesis in a patient in need of anti-angiogenesis therapy, a solvent, and a pharmaceutically acceptable carrier. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A.

Abstract: There is provided a pharmaceutical preservative free composition suitable for topical administration to an eye, the composition comprising (a) an oxazolidinone antimicrobial drug, for example linezolid, in a therapeutically or prophylactically effective drug concentration that is above the practical limit of solubility of the drug in a substantially isotonic aqueous solution at a physiologically compatible pH, and (b) a pharmaceutically acceptable cyclodextrin compound in a concentration sufficient to maintain the drug in solution at such a drug concentration. The composition is particularly useful for the treatment and/or prevention of eye infections due to gram positive bacteria.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists, processes for preparing them and their use in the treatment of respiratory tract diseases.

Abstract: Novel accelerated methods involving corona discharge, and preferably pulsed streamer high voltage corona discharge, in combination with an effective amount of suitable particles to break down organic contaminants, such as phenol and phenol red, in aqueous mediums are disclosed. More particularly, it has been discovered that the addition of an effective amount of suitable particles to the aqueous phase of a corona reactor greatly affects the properties of the corona discharge, i.e., streamer length, intensity, number of streamers and sparkover voltage, thereby significantly increasing the breakdown voltage (i.e., the maximum voltage prior to sparkover), so that the removal of organic contaminants may be accelerated, since the production of hydroxyl radicals, aqueous electrons and hydrogen peroxide increases with increases in the applied discharge voltage.

Abstract: The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.

Abstract: The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by wherein R is alkyl or aryl, the compound is trans-across the epoxide ring, OX is a carbonyl (═O) or hydroxy group (OH) and R′ is a H, alkyl or aryl group. The invention further provides methods of identifying patients at increased risk for hypertension, comprising assaying for epoxide hydrolase activity in a urine sample from the patient. In particular, the assays comprise determining the amount of dihydroxyeicosatrienoic acids (DHETs), determining the amount of epoxyeicosatrienoic acids (EETs) in said sample, or determining the amount of both DHETs and EETs in said sample.

Abstract: This invention provides a process for preparing sodium ferric gluconate complex in sucrose using the following steps: a) combining a ferric salt solution with a weak alkali chosen from the group consisting of alkaline earth metal and ammonium salts, such as sodium carbonate, sodium bicarbonate, lithium carbonate, potassium carbonate, potassium bicarbonate, ammonium carbonate, ammonium bicarbonate and mixtures thereof, to form the ferric oxyhydroxide; b) combining ferric oxyhydroxide and sodium gluconate in solution to yield the sodium ferric gluconate complex; c) isolating the sodium ferric gluconate complex; and d) combining the sodium ferric gluconate with sucrose in solution to yield the desired sodium ferric gluconate complex in sucrose.

Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as naphthoic acid derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokine may for example be stromal cell-derived factor (SDF)-1, and the relevant chemokine receptors may for example be corresponding chemokine receptor (CXCR-4). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of 3-Hydroxy-2-naphthoic acid in the treatment of disease.

Abstract: The present invention provides methods and compositions for preventing and treating inflammation-associated disorders or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family of proteases. Also provided are compositions useful for these purposes. Exemplary compounds useful in the methods of the invention are provided herein.

Abstract: A method of potentiating radiation therapy in a subject in need thereof comprises administering a potentiating agent such as caffeic acid phenethyl ester (CAPE) or an analog thereof to the subject in an amount effective to potentiate radiation therapy in the subject.

Abstract: The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.

Abstract: The present invention provides a pharmaceutical composition comprising pemetrexed; at least one antioxidant selected from the group consisting of monothioglycerol, L-cysteine, and thioglycolic acid; and a pharmaceutically acceptable excipient. The pharmaceutical formulation is suitable for liquid parenteral administration.

Abstract: Compounds according to the formula as defined herein are administered for the treatment of irritable bowel syndrome and nonulcer dyspepsia.

Abstract: This invention is directed to a process for inhibiting aggrecanase activity. The process comprises administering a therapeutically effective amount of a sulfonyl aromatic or heteroaromatic hydroxamic acid, a derivative thereof, or a pharmaceutically acceptable salt of the hydroxamic acid or derivative to a host animal. The compound generally corresponds in structure to the following formula: wherein W and the R groups are described in more detail in Applicants' specification.

Abstract: The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of quercetin, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had previously been treated for prostate cancer. Methods of the invention further include treating an individual with benign prostatic hyperplasia (BPH) with quercetin as well as methods of screening for compounds that inhibit the proliferation of prostate cancer cells. The invention provides for compositions and articles of manufacture containing quercetin in particular formulations, and quercetin with a second compound that also exerts an effect on the androgen receptor.

Abstract: Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.

Abstract: The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.

Abstract: The present invention relates to a method of inhibiting carcinoma progression wherein matriptase plays a role in a subject in need of such inhibition including administering to a subject an effective amount of a compound comprising two positively charged groups, which are the same or different. The groups are linked by a chemical group having a length of between 5 and 30 A, and preferably between 15 and 24 A. Diagnostic methods based on matriptase action and therapeutic methods involving inhibition of matriptase activity are provided.

Abstract: Broad-spectrum anti-emetic pharmaceutical compositions are disclosed. The discloses broad-spectrum ant-emetics disclosed herein comprise selected neuroreceptor antagonists specifically formulated to treat and prevent to most common forms of emesis. In one embodiment the ant-emetic compositions include lorazepam, diphenhydramine, promethazine, and metoclopramide. The pharmaceutical compositions include, but are not limited to oral and parenteral forms and may include one or more pharmaceutically acceptable excipient.